Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Natalizumab: A Double-Edged Sword?
Ann Neurol 66:262-263, DeAngelis,L., 2009
Diffuse Pontine Glioma
UpToDate, April, Kieran,M.W., 2006
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Brainstem Gliomas in Adults: Prognostic Factors and Classification
Brain 124:2528-2539, Guillamo,J.-S.,et al, 2001
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Stridor in Multiple System Atrophy
Neurol 93:630-639, Cortelli, P.,et al, 2019
Neuromyelitis Optica: Evaluation of 871 Attacks and 1,153 Treatment Courses
Ann Neurol 79:206-216,204, Kleiter, I.,et al, 2016
Cervical Arterial Dissections and Association with Cervical Manipulative Therapy
Stroke 45:3156-3174, Biller, J.,et al, 2014
Thrombolysis for Acute Ischemic Stroke in Patients with Cancer
Stroke 44:3573-3576, Murthy, S.B.,et al, 2013
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Routine HIV Screening - What Counts in Evidence-Based Policy?
NEJM 365:1265-1268, Bayer, R. and Oppenheimer G.M., 2011
Open Biopsy in Patients With Acute Progressive Neurologic Decline and Absence of Mass Lesion
Neurol 75:419-424, Schuette,A.J., et al, 2010
AIDS - Related Lymphomas: Primary CNS Lymphoma
UpToDate, April, Doweiko, J.P., 2010
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Corticosteroids for Acute Bacterial Meningitis
NEJM 357:2507-2509, Greenwood,B.M., 2007
What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
Stiff-Person Syndrome
The Neurologist 10:131-137, Murinson,B.B., 2004
Potassium Channel Antibody-Associated Encephalopathy: A Potentially Immunotherapy-Responsive Form of Limbic Encepahlitis
Brain 127:701-712, Vincent,A.,et al, 2004
Therapeutic Dilemma
Neurol 54:1404-1407, Romanelli,F.,et al, 2000
Significance of Surgical Resection for the Treatment of Multiple Brain Metastases
Anticancer Res 20:573-577, Iwadate,Y.,et al, 2000
Use of Corticosteroids in Multiple Sclerosis by Consultant Neurologists in the United Kingdom
JNNP 54:362-365, Tremlett,H.L.,et al, 1998
Intracranial Mass Lesions in AIDS:Using Decision Analysis to Determine the Effectiveness of Stereotactic Brain Biopsy
Neurol 46:1010-1015, Holloway,R.G.,et al, 1996
Consensus and Controversy in Neurologic Practice, The Case of Steroid Treatment in Multiple Sclerosis
Arch Neurol 46:322, Menken,M., 1989
Antithrombotic Therapy in Patients with Cerebral Microbleeds or Cortical Siderosis, Is This Contraindicated?
Neurol 100:551-552, Schneck,M.J., &Biller,J., 2023
Management of Possible Multiple Sclerosis
NEJM 388:2195-2190, , 2023
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Trial of Dexamethasone for Chronic Subdural Hematoma
NEJM 383:2616-2627,2678, Hutchinson, P.J.,et al, 2020
Links in the Chain of Chronic Traumatic Encephalopathy
NEJM 380:1771-1772, Ropper, A.H., 2019
Neurological Manifestations Among US Government Personnel Reporting Directional Audible and Sensory Phenomena in Havana, Cuba
JAMA 319:1125-1133, 1098, 1079, Swanson, R.L.,et al, 2018
Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome
JAMA Neurol 75:353-359, Martinez-Ramirez, D.,et al, 2018
Diagnosis of Multiple Sclerosis: Progress and Challenges
Lancet 389:1336-1346, Brownlee, W.J.,et al, 2017
Arteriovenous Malformations of the Brain
NEJM 376:1859-1866, Solomon, R.A. & Connolly, E.S., 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Infective Endocarditis
Lancet 387:882-893, Cahill, T.J. & Prendergast, B.D., 2016
Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016
Repeated Intravenous Thrombolysis for Early Recurrent Stroke
Stroke 47:2133-2135, Kahles, T.,et al, 2016
Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension
NEJM 375:1119-1130,1183, Hutchinson, P.J.,et al, 2016
Dexamethasone & Supportive Care with or without Whole Brain Radiotherapy in Treating Patients with Non-Small Cell Lung Cancer with Brain Metastases Unsuitable for Resection or Stereotactic Radiotherapy (QUARTZ): Results from a Phase 3,Non-Inferiority, Randomised Trial
Lancet 388:2004-2014, Mulvenna, P.,et al, 2016
Clinicopathologic Conference, Oligdendroglioma II/IV with IDH1 R132H mutation and codelation of 1p and 19q
NEJM 375:2381-2389, Case 38-206, 2016
Responsibilities of Health Care PRofessionals in Counseling and Educating Patients with Incurable Neurological Diseases Regarding "Stem Cell Tourism"
JAMA Neurol 72:1342-1345, Bowman, M.,et al, 2015
Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:e103-e104, Fox, R.J., 2014
Hemicraniectomy in Older Patients with Extensive Middle-Cerebral-Artery Stroke
NEJM 370:1091-1100,1159, Juttler, E.,et al, 2014
Should Doctors Prescribe Cannabinoids?
BMJ 348:g2737, Farrell, M.,et al, 2014